The PCA3 test is a simple urine sample collected following a digital rectal exam for the determination of the PCA3 score. Specific for prostate cancer,
and, unlike the PSA, this test is not affected by prostate enlargement
or other non-cancerous prostate conditions. In combination with PSA and
DRE results, the PCA3 score provides useful information to help decide
if a biopsy is needed, or can be delayed. It's much more specific in
giving additional information about the aggressiveness of the cancer if
the patient has a positive biopsy.
"This
new genetic test is a great next step for some men with an elevated
PSA. The purpose of this tumor marker test is to reduce unnecessary
biopsies. Not every elevated PSA
translates to the need for a biopsy. The PCA3 test was specifically
developed to address the criticisms of the PSA being non-specific to
prostate cancer. Combined with the PSA and DRE, this new genetic test
helps lead to a more optimized decision to perform the biopsy," stressed
Dr. David Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital in New York City.
The
PCA3 test is not meant to replace the PSA test. It is simply an
additional tool used to provide a more accurate picture and prediction
of whether prostate cancer is present or not.
No comments:
Post a Comment